Tumor burden score predicts tumor recurrence of non-functional pancreatic neuroendocrine tumors after curative resection. HPB : the official journal of the International Hepato Pancreato Biliary Association Dong, D., Zhang, X., Lopez-Aguiar, A. G., Poultsides, G., Makris, E., Rocha, F., Kanji, Z., Weber, S., Fisher, A., Fields, R., Krasnick, B. A., Idrees, K., Smith, P. M., Cho, C., Beems, M., Schmidt, C. R., Dillhoff, M., Maithel, S. K., Pawlik, T. M. 2019


BACKGROUND: To investigate the feasibility of Tumor Burden Score (TBS) to predict tumor recurrence following curative-intent resection of non-functional pancreatic neuroendocrine tumors (NF-pNETs).METHOD: The TBS cut-off values were determined by a statistical tool, X-tile. The influence of TBS on recurrence-free survival (RFS) was examined.RESULTS: Among 842 NF-pNETs patients, there was an incremental worsening of RFS as the TBS increased (5-year RFS, low, medium, and high TBS: 92.0%, 73.3%, and 59.3%, respectively; P<0.001). TBS (AUC 0.74) out-performed both maximum tumor size (AUC 0.65) and number of tumors (AUC 0.5) to predict RFS (TBS vs. maximum tumor size, p=0.05; TBS vs. number of tumors, p<0.01). The impact of margin (low TBS: R0 80.4% vs. R1 71.9%, p=0.01 vs. medium TBS: R0 55.8% vs. R1 37.5%, p=0.67 vs. high TBS: R0 31.9% vs. R1 12.0%, p=0.11) and nodal (5-year RFS, low TBS: N0 94.9% vs. N1 68.4%, p<0.01 vs. medium TBS: N0 81.8% vs. N1 55.4%, p<0.01 vs. high TBS: N0 58.0% vs. N1 54.2%, p=0.15) status on 5-year RFS outcomes disappeared among patients who had higher TBS.CONCLUSIONS: TBS was strongly associated with risk of recurrence and outperformed both tumor size and number alone.

View details for DOI 10.1016/j.hpb.2019.11.009

View details for PubMedID 31822386